Eurofarma Laboratórios S.A. agreed to acquire Genfar S.A. from Sanofi (ENXTPA:SAN) for approximately ?300 million on March 7, 2023. The transaction includes Genfar and its affiliates, which includes the companies Genfar S.A. and Genfar Desarollo y Manufactura S.A., headquartered in Colombia, Genfar del Ecuador S.A.S., headquartered in Ecuador and Genfar del Peru S.A.C., headquartered in Peru. Agustin Vincent, Genfar General Manager, will continue to chair the company that accumulates a portfolio of 350 products, 114 molecules and 12 different therapeutic categories.

The transaction is subject to regulatory approvals, including applicable antitrust approvals and other customary closing conditions. Banco Itaú BBA S.A. acted as the financial advisor to Eurofarma Laboratórios S.A. Lazard, Inc. acted as the financial advisor to Genfar S.A.